Front > HEALTHCARE

HEALTHCARE

Kare Schultz Photo: PR Teva closes Washington lobbying office

Teva spent $5.6 million on lobbying in 2017 and has spent $37 million over the past 10 years.

Teva Photo: Reuters Ammar Awad Outrage as Teva charges $18,275 for generic drug in US

Valeant charges $21,267 for 100 branded Syprine tablets. Bernie Sanders: Do we have the guts to stand up to drug companies who are ripping us off?

Treatment at Alyn Hospital ALYNnovation: 'Impossible' is not in our vocabulary

ALYNnovation takes medical innovations developed at the ALYN pediatric rehabilitation hospital out of the hospital so that all children can benefit from them.

Teva Photo: Reuters Teva's troubles reflected in high bond yields

Leader Capital Market: There is great uncertainty about Teva's future growth potential.

Merck photo: PR Merck sets up €20m fund for Israeli biotech cos

The German pharmaceutical company is cooperating with Arkin Bio Ventures, Pontifax Fund, and WuXi Apptec.

Vaica Photo: PR Vaica reminds patients to take medicine

The Israeli company adapts its reminders to the patient's age and the type of medicine.

Ziv Aviram and Prof. Amnon Shashua Mobileye founders co OrCam valued at over $1b

OrCam, which has developed a wearable aid for people with impaired vision, raised $30.4 million in a round led by Clal Insurance and Meitav Dash Provident Funds and Pension Ltd.

Nasdaq Photo: Reuters Colonoscopy device co Motus GI raises $17.5m on Nasdaq

Tirat Hacarmel based Motus GI has developed Pure-Vu for cleaning the colon in advance of a colonoscopy.

medical equipment  photo: Shutterstock Neurovascular device co Perflow Medical raises $12m

Stream Net is a thrombectomy device designed to address unmet clinical needs in the treatment of acute ischemic stroke.

Freddy Zinger Photo: Eyal Yitzhar Former Teva exec sets up Galilee incubator

Freddy Zinger does not rule out buying Teva Migada in Kiryat Shmona, the company he founded.

Kare Schultz Photo: PR Teva share price up 75% since Schultz became CEO

Kare Schultz has stabilized the ship but faces enormous opposition to his streamlining plan.

Teva Photo: Reuters Teva: Healthy business, sick share

Every change in Teva's business is amplified in its share price.

Prof Eyal Winter  photo: private Israeli drug exploration partnership can save Teva

Teva, Israel's universities and the state should join forces to find and develop new drugs, says Prof. Eyal Winter.

Teva workers demonstrate  photo: courtesy Histadrut Economic damage from Teva's cutbacks will mainly be local

Teva's contribution to Israel's tax revenues has been virtually zero.

Teva Photo: Tamar Matsafi Most Teva Israel layoffs expected at Petah Tikva HQ

As Teva workers await the axe, one tells "Globes" that he fears he will be shortchanged while outgoing CSO Michael Hayden gets $2.5 million by the end of 2018.

Teva Photo: Tamar Matsafi "Teva's senior execs should pay back excessive salaries"

Former Teva chairman Meir Heth believes the company's top executives are responsible for the current situation.

Teva Photo: Tamar Matsafi US hedge funds reduce Teva exposure

Some financial institutions see an opportunity in Teva's low share price and have increased their holdings in the company.

Dalton Conley Photo: PR "Genetic inequality is increasing"

Princeton University's Prof. Dalton Conley tells "Globes" that understanding the interaction between genetics and environment will start a social revolution.

Teva  photo: Reuters Poalim IBI: Teva must raise capital

Analyst Steven Tepper tells "Globes" that if Teva wants to stay independent, it needs capital, or it will be exposed to a takeover.

Prof. Zelig Eshar Photo: Shlomi Yosef Israeli professors fight for Kite Pharma sale spoils

Prof. Gideon Gross is suing Prof. Zelig Eshhar, alleging that Eshhar cheated him out of his share of the $11.9 billion sale of Kite, which has developed a revolutionary cancer drug.

Arie Belldegrun Photo: PR "Chemotherapy will become just a bad memory"

More energetic than ever, Arie Belldegrun talks to "Globes" about Kite Pharma's remarkable journey and the future of cancer treatment.

Mori Arkin, Uri Geiger photos: Tamar Matsafi, Eyal Izhar Accelmed fattening Cogentix for sale

Accelmed seeks to replicate its success formula in urology, as portfolio company Cogentix makes a third acquisition.

Essence Group  photo: PR Smart home means safe home for seniors

Israeli company Essence develops products that enable people to keep living at home in old age.

Prof Michal Schwartz photo: Rami Zarnegar "Lady Globes" Woman of the Year: Prof. Michal Schwartz

The Weizmann Institute researcher's groundbreaking research on Alzheimer's Disease is leading to new treatment for it.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018